Riccardo Valdez

This study assesses whether 2025 COVID-19 vaccines need updating by testing neutralizing antibody titers against emerging variants in individuals vaccinated with KP.2-based mRNA vaccines.

This study evaluates the antibody evasion of SARS-CoV-2 subvariants KP.3.1.1 and XEC compared to their parental variants, finding increased resistance to neutralization by sera and antibodies targeting the spike protein.

This study evaluates KP.2-based monovalent mRNA vaccines and finds they robustly boost neutralizing antibodies against current SARS-CoV-2 variants, including KP.3.1.1 and XEC.

This study examines how recurrent spike mutations in SARS-CoV-2 JN.1 sublineages affect immune evasion, ACE2 affinity, and infectivity, identifying growth advantages in specific sublineages.

This study shows that neutralizing antibodies against SARS-CoV-2 variants remain stable for three months after an XBB.1.5 mRNA vaccine booster.

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.